The total cases of Programmed Death-Ligand 1 (PD-L1) mutated Non-small Cell Lung Cancer (NSCLC) in the 7MM were observed to be 242,014 in 2017.
The therapeutic market size of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in seven major markets was found to be USD 6,536 million in 2017 which is expected to increase during the study period (2017–2030).
Increasing use of biomarker testing, increase in the mutation specific trials activity, increasing incidence of Programmed Death Ligand 1 (PD-L1) mutated NSCLC are some of the key factors expected to drive the PD-L1 NSCLC Market in the upcoming years.
The key players in the PD-L1 NSCLC Market include Pfizer/Merck, Regeneron Pharmaceuticals, Novartis, GlaxoSmithKline and others.
For more detailed information on PD-L1 NSCLC Market, visit: